Silence Therapeutics Plc Financials
Silence Therapeutics Plc (SLN) reported $559K in revenue for fiscal year 2025, down 98.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A development-stage R&D model dominates, with cash burn driven far more by research spending than by recurring revenue.
The swing from$43.3M of revenue in FY2024 to just$559K in FY2025 barely changed the cost base: R&D spend held near$67.8M and operating cash burn remained-$62.3M . That makes reported revenue look episodic rather than load-bearing, so FY2024’s$142.1M financing inflow functioned more like a temporary fuel tank than evidence the business had started funding itself.
FY2025 still shows paper liquidity: current assets of
Leverage worsened mainly because equity was consumed by losses, not because liabilities expanded; total liabilities stayed near
Financial Health Signals
Silence Therapeutics Plc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Silence Therapeutics Plc scores -0.15, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($826.0M) relative to total liabilities ($69.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Silence Therapeutics Plc passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Silence Therapeutics Plc reported a net loss of $88.6M while operations used $62.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Silence Therapeutics Plc generated $559K in revenue in fiscal year 2025. This represents a decrease of 98.7% from the prior year.
Silence Therapeutics Plc's EBITDA was -$90.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 44.1% from the prior year.
Silence Therapeutics Plc reported -$88.6M in net income in fiscal year 2025. This represents a decrease of 95.6% from the prior year.
Silence Therapeutics Plc earned -$0.63 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 90.9% from the prior year.
Cash & Balance Sheet
Silence Therapeutics Plc recorded an outflow of $62.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 8.1% from the prior year.
Silence Therapeutics Plc held $11.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Silence Therapeutics Plc's gross margin was 61.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 11.2 percentage points from the prior year.
Silence Therapeutics Plc's ROE was -142.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 108.4 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Silence Therapeutics Plc invested $67.8M in research and development in fiscal year 2025. This represents a decrease of 0.2% from the prior year.
Silence Therapeutics Plc invested $55K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 73.9% from the prior year.
Not reported for fiscal year 2025.
SLN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Revenue | $615K | $559K-98.7% | $43.3M+36.7% | $31.6M+46.1% | $21.7M |
| Cost of Revenue | $87K | $215K-98.2% | $11.8M-8.2% | $12.9M-4.4% | $13.5M |
| Gross Profit | $528K | $344K-98.9% | $31.4M+67.5% | $18.8M+129.2% | $8.2M |
| R&D Expenses | $47.6M | $67.8M-0.2% | $67.9M+19.2% | $56.9M+30.7% | $43.5M |
| SG&A Expenses | $21.3M | $22.3M-16.9% | $26.9M+2.5% | $26.2M+2.1% | $25.7M |
| Operating Income | -$68.3M | -$91.1M-43.8% | -$63.3M+1.7% | -$64.4M-5.5% | -$61.0M |
| Income Tax | $2K | $11K-98.7% | $845K-11.6% | $956K+39.0% | $688K |
| Net Income | -$60.0M | -$88.6M-95.6% | -$45.3M+16.4% | -$54.2M-7.7% | -$50.3M |
| EPS (Diluted) | — | -$0.63-90.9% | -$0.33+32.7% | -$0.49+5.8% | -$0.52 |
Not reported in any period shown, so not listed: Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SLN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Total Assets | $131.4M-35.1% | $202.6M+69.6% | $119.4M | N/A |
| Current Assets | $118.7M-36.7% | $187.4M+81.6% | $103.2M | N/A |
| Cash & Equivalents | $11.3M-90.7% | $121.3M+76.4% | $68.8M | N/A |
| Accounts Receivable | $0-100.0% | $972K+235.2% | $290K | N/A |
| Goodwill | $10.6M+13.1% | $9.4M-5.9% | $10.0M+3.1% | $9.7M |
| Total Liabilities | $69.1M+0.8% | $68.6M-29.6% | $97.5M | N/A |
| Current Liabilities | $13.6M-19.1% | $16.8M-24.7% | $22.3M | N/A |
| Total Equity | $62.3M-53.5% | $134.0M+509.4% | $22.0M-19.2% | $27.2M |
| Retained Earnings | -$562.6M-18.7% | -$474.0M-9.8% | -$431.9M | N/A |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
SLN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$42.3M | -$62.3M+7.9% | -$67.6M-36.8% | -$49.5M+13.3% | -$57.0M |
| Capital Expenditures | $3K | $55K-73.9% | $211K+276.8% | $56K-67.6% | $173K |
| Free Cash Flow | -$42.3M | -$62.3M+8.1% | -$67.9M-37.0% | -$49.5M+13.5% | -$57.2M |
| Investing Cash Flow | $72.9M | -$48.0M-118.5% | -$22.0M-213.8% | $19.3M+194.1% | -$20.5M |
| Financing Cash Flow | $2K | $15K-100.0% | $142.1M+344.9% | $31.9M-39.3% | $52.6M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SLN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Gross Margin | 61.5%-11.2pp | 72.7%+13.4pp | 59.3%+21.5pp | 37.8% |
| Operating Margin | -16292.8% | -146.4% | -203.5% | -281.9% |
| Net Margin | -15851.5% | -104.7% | -171.4% | -232.4% |
| Return on Equity | -142.2%-108.4pp | -33.8%+212.8pp | -246.6%-61.7pp | -184.9% |
| Return on Assets | -67.4%-45.1pp | -22.4%+23.0pp | -45.4% | N/A |
| Current Ratio | 8.72-2.4x | 11.14+6.5x | 4.62 | N/A |
| Debt-to-Equity | 1.11+0.6x | 0.51-3.9x | 4.43 | N/A |
| FCF Margin | -11149.6% | -156.8% | -156.5% | -264.2% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Silence Therapeutics Plc Ranks
Frequently Asked Questions
What is Silence Therapeutics Plc's annual revenue?
Silence Therapeutics Plc (SLN) reported $559K in total revenue for fiscal year 2025. This represents a -98.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Silence Therapeutics Plc's revenue growing?
Silence Therapeutics Plc (SLN) revenue declined by 98.7% year-over-year, from $43.3M to $559K in fiscal year 2025.
Is Silence Therapeutics Plc profitable?
No, Silence Therapeutics Plc (SLN) reported a net income of -$88.6M in fiscal year 2025.
What is Silence Therapeutics Plc's EBITDA?
Silence Therapeutics Plc (SLN) had EBITDA of -$90.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Silence Therapeutics Plc's gross margin?
Silence Therapeutics Plc (SLN) had a gross margin of 61.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Silence Therapeutics Plc's return on equity (ROE)?
Silence Therapeutics Plc (SLN) has a return on equity of -142.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Silence Therapeutics Plc's free cash flow?
Silence Therapeutics Plc (SLN) recorded an outflow of $62.3M in free cash flow during fiscal year 2025. This represents a 8.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Silence Therapeutics Plc's operating cash flow?
Silence Therapeutics Plc (SLN) recorded an outflow of $62.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Silence Therapeutics Plc's total assets?
Silence Therapeutics Plc (SLN) had $131.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Silence Therapeutics Plc's capital expenditures?
Silence Therapeutics Plc (SLN) invested $55K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Silence Therapeutics Plc spend on research and development?
Silence Therapeutics Plc (SLN) invested $67.8M in research and development during fiscal year 2025.
What is Silence Therapeutics Plc's current ratio?
Silence Therapeutics Plc (SLN) had a current ratio of 8.72 as of fiscal year 2025, which is generally considered healthy.
What is Silence Therapeutics Plc's debt-to-equity ratio?
Silence Therapeutics Plc (SLN) had a debt-to-equity ratio of 1.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Silence Therapeutics Plc's return on assets (ROA)?
Silence Therapeutics Plc (SLN) had a return on assets of -67.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Silence Therapeutics Plc's cash runway?
Based on fiscal year 2025 data, Silence Therapeutics Plc (SLN) had $11.3M in cash against an annual operating cash burn of $62.3M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Silence Therapeutics Plc's Altman Z-Score?
Silence Therapeutics Plc (SLN) has an Altman Z-Score of -0.15, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Silence Therapeutics Plc's Piotroski F-Score?
Silence Therapeutics Plc (SLN) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Silence Therapeutics Plc's earnings high quality?
Silence Therapeutics Plc (SLN) reported a net loss of $88.6M while operations used $62.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.